Study of AZD9829 in CD123+ Hematological Malignancies

Launched by ASTRAZENECA · Dec 19, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called AZD9829 for patients with certain blood cancers that have a specific marker called CD123. This study is in the early phases and aims to find the best dose of AZD9829, which may be given alone or with other treatments. It is currently open to adults aged 18 and older who have specific types of blood cancers, such as relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS). To be eligible, participants should have already tried at least one other treatment that didn’t work and should not have any other treatment options available.

If you join this trial, you will receive AZD9829 through an intravenous (IV) line, and the study team will closely monitor your health and the treatment's effects. It’s important to know that there are some criteria that could exclude you from participating, such as having an active central nervous system leukemia, previous treatments targeting CD123, or certain other serious health issues. This trial is actively recruiting participants, so if you meet the eligibility requirements and are interested, it could be a potential option for you or your loved one.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years of age;
• • CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory;
• • R/R AML (except APL);
• • R/R HR-MDS with ≥5% bone marrow blast at time of inclusion;
• • Had at least 1 prior line of therapy at currents histology, and have no available treatment options;
• • ECOG performance status of ≤ 2.
• • The above is a summary, other inclusion criteria details may apply.
• Exclusion Criteria:
• • Active CNS leukemia;
• • Previous treatment with any CD123 targeting therapy;
• • Prior allogeneic HSCT, within 90 or cell therapy within 60 of start of therapy;
• • Active GVHD that requires immunosuppressive treatment within 4 weeks prior to start of AZD9829;
• • History of other malignancy(with certain exceptions);
• • Active and uncontrolled infections;
• • Unresolved AEs ≥2 Grade, from prior therapies.
• • The above is a summary, other exclusion criteria details may apply.